top of page

With unique license agreements in place with local universities and an additional $260M recently raised, Cambridge, UK based Apollo Therapeutics is building out a substantial pipeline

Feb 26, 2025
1 min read

CEO Richard Mason describes the company's philosophy, and covers programs such as a FGF21/GLP-1 that was recently licensed from a Chinese partner, an IL18, ZIP12, and more.




Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page